These findings identify the therapeutic effects of CBP‐Exos are attributed to the miR‐410‐3p/Bcl2/CytoC axis, laying a foundation for the clinical application of CBP‐Exos and miR‐410‐3p in liver diseases. This evidence concerns the gene BCL2 and liver disorder.